InsiderTrades.com logo
Ashish Mandelia net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Ashish Mandelia Biography and Net Worth

VP of Mersana Therapeutics
Ashish Mandelia is the VP, Controller & Principal Accounting Officer at Mersana Therapeutics Inc.

What is Ashish Mandelia's net worth?

The estimated net worth of Ashish Mandelia is at least $21,828.46 as of January 16th, 2025. Mr. Mandelia owns 57,519 shares of Mersana Therapeutics stock worth more than $21,828 as of March 31st. This net worth evaluation does not reflect any other assets that Mr. Mandelia may own. Learn More about Ashish Mandelia's net worth.

How old is Ashish Mandelia?

Mr. Mandelia is currently 49 years old. There are 5 older executives and no younger executives at Mersana Therapeutics. The oldest executive at Mersana Therapeutics is Dr. Martin H. Huber M.D., President, CEO & Director, who is 63 years old. Learn More on Ashish Mandelia's age.

How do I contact Ashish Mandelia?

The corporate mailing address for Mr. Mandelia and other Mersana Therapeutics executives is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. Mersana Therapeutics can also be reached via phone at (617) 498-0020 and via email at ir@mersana.com. Learn More on Ashish Mandelia's contact information.

Has Ashish Mandelia been buying or selling shares of Mersana Therapeutics?

Over the course of the past ninety days, Ashish Mandelia has sold $2,725.94 in shares of Mersana Therapeutics stock. Most recently, Ashish Mandelia sold 3,554 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $0.58, for a transaction totalling $2,061.32. Following the completion of the sale, the chief accounting officer now directly owns 57,519 shares of the company's stock, valued at $33,361.02. Learn More on Ashish Mandelia's trading history.

Who are Mersana Therapeutics' active insiders?

Mersana Therapeutics' insider roster includes Lawrence Alleva (Director), Andrew Hack (Director), Timothy Lowinger (Insider), Ashish Mandelia (VP), Anna Protopapas (CEO), and Arvin Yang (Insider). Learn More on Mersana Therapeutics' active insiders.

Are insiders buying or selling shares of Mersana Therapeutics?

During the last twelve months, insiders at the sold shares 12 times. They sold a total of 111,626 shares worth more than $154,116.74. The most recent insider tranaction occured on January, 16th when CAO Ashish Mandelia sold 3,554 shares worth more than $2,061.32. Insiders at Mersana Therapeutics own 11.8% of the company. Learn More about insider trades at Mersana Therapeutics.

Information on this page was last updated on 1/16/2025.

Ashish Mandelia Insider Trading History at Mersana Therapeutics

See Full Table

Ashish Mandelia Buying and Selling Activity at Mersana Therapeutics

This chart shows Ashish Mandelia's buying and selling at Mersana Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$2.73ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20k-$10k$0$10k$20kTotal Insider BuyingTotal Insider Selling

Mersana Therapeutics Company Overview

Mersana Therapeutics logo
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $0.38
Low: $0.37
High: $0.42

50 Day Range

MA: $0.54
Low: $0.37
High: $0.75

2 Week Range

Now: $0.38
Low: $0.37
High: $4.64

Volume

4,774,853 shs

Average Volume

2,402,365 shs

Market Capitalization

$47.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67